BARDA Awards $51.9 Million Contract to DNAe
News Oct 05, 2016
DNA Electronics (‘DNAe’), the inventors of semiconductor-based next- generation DNA sequencing (NGS) technology and developers of a revolutionary blood-to-result test for blood stream infections, announce s that t he Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) has awarded the Company a contract worth up to $51.9 million to develop its sequencing platform for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.
Genomic information derived from DNA sequencing is transforming many areas of medicine. This is the first NGS platform supported by BARDA, with game-changing potential in the diagnosis and treatment of infectious diseases.
The contract for the project entitled PISCES (Pathogen Identification from Specimen, via Capture Extraction and Sequencing) will enable DNAe to complete the development and validation of its ground -¬‐ breaking Genalysis® platform and support a series of application s to the U.S. Food and Drug Administration for marketing clearance.
The Genalysis® platform will combine the ability to sequence the DNA of the infectious organism, in a sealed microchip based system, direct from clinical specimen, with analysis that enables actionable identification of the disease agent within a few hours, a key requirement in the effective treatment of infectious diseases.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019